Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy

STATUS

Recruiting
participants needed

300
sponsor

Rush Eye Associates

Send

Updated on 19 February 2024

See if I qualify

diabetes

retinopathy

diabetic retinopathy

retinal detachment

detachment

vitrectomy

internal limiting membrane peeling

proliferative diabetic retinopathy

Summary

Subject/Participant Groups:

Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment

Description

Hypothesis

Subjects undergoing ILM peeling during vitrectomy will have lower central macular thickness on OCT and lower rates of DME, fewer postoperative epiretinal membranes, and thereby better final visual acuity to control subjects Randomization: Subjects will be randomized according to a coin toss during PPV, once Grade 2 or Grade 3 vitreoretinal adhesion has been determined: heads undergo ILM peeling, while tails do not.

Number of Subjects: With study power of 80%, a significance level of 0.05, a sample size of 60 patients for each group was calculated.

Details

Condition	Diabetic Retinopathy, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Macular Edema
Age	18years - 85years
Treatment	ILM Peeling, No ILM Peeling
Clinical Study Identifier	NCT04380064
Sponsor	Rush Eye Associates
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Subject age is 18-85 years.'
	b'Subject consents to study participation and is capable of 6 months of follow-up.'
	b'The subject has type I or II Diabetes Mellitus with active PDR in the study eye.'
	b'Best-corrected spectacle visual acuity (BCSVA) on the Snellen eye chart ranges from'
	b'20/40 to hand motions in the study eye.'
	b'The subject is determined to need a PPV for the indication of TRD (Grades 2 and 3).'
Exclusion Criteria
	b'Subject is known to have a significant retinal/optic nerve disease otherwise unrelated'
	b'to Diabetes Mellitus, which in the opinion of the examiner is responsible for two or'
	b'more lines of reduced BCSVA (macular degeneration, optic neuritis, glaucoma,'
	b'amblyopia, etc.) in the study eye.'
	b'Subject is known to have macular ischemia, which in the opinion of the examiner, is'
	b'responsible for two or more lines of reduced BCSVA in the study eye.'
	b'Subject has a significant corneal or cataract opacity, which in the opinion of the'
	b'examiner, is responsible for two or more lines of reduced BCSVA (corneal scar,'
	b'ectasia, etc.) in the study eye.'
	b'Subject has had a previous vitrectomy (anterior or PPV) in the study eye.'
	b'Subject has uncontrolled neovascular glaucoma (intraocular pressure > 30 mmHg despite'
	b'medical/surgical treatment) in the study eye.'
	b'Subject has uncontrolled hypertension (systolic > 200 mmHg or diastolic > 120 mmHg)'
	b'despite adherence to a multiple anti-hypertensive medication regimen.'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

internal limiting membrane peeling

proliferative diabetic retinopathy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy